Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rMAGE-3
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
rMAGE-3 is a recombinant protein-based therapeutic vaccine candidate targeting the melanoma-associated antigen 3 (MAGE-A3), which is expressed in various tumors but not in normal tissues except for testis and placenta. The drug is designed to stimulate an immune response against cancer cells expressing the MAGE-A3 antigen. It has been investigated primarily as an immunotherapy for cancers such as melanoma and non-small cell lung cancer. The mechanism of action involves presenting the MAGE-A3 antigen to the immune system, thereby inducing cytotoxic T lymphocyte responses that target and destroy tumor cells expressing this antigen.
- Other names
- recombinant MAGE-A3 proteinMAGE-A3 proteinMAGE-A-3 proteinMAGE-A 3 proteinrecombinant melanoma-associated antigen 3
02
Targets
MAGEA3 (Melanoma-associated antigen 3)
Beyond the preview
Go deeper on rMAGE-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rMAGE-3.